AMCA
DNLI icon

Arthur M. Cohen & Associates’s Denali Therapeutics DNLI Stock Holding History

Arthur M. Cohen & Associates’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,564
Closed -$227K – 136
2023
Q4 		$227K Sell
10,564
-2,377
-18% -$47.1K 0.05% 123
2023
Q3 		$267K Sell
12,941
-8,189
-39% -$208K 0.07% 110
2023
Q2 		$624K Buy
21,130
+3,651
+21% +$103K 0.15% 72
2023
Q1 		$403K Buy
17,479
+2,141
+14% +$58.9K 0.11% 88
2022
Q4 		$427K Hold
15,338
– – 0.12% 91
2022
Q3 		$471K Buy
15,338
+2,922
+24% +$95K 0.13% 84
2022
Q2 		$365K Hold
12,416
– – 0.09% 98
2022
Q1 		$399K Hold
12,416
– – 0.08% 98
2021
Q4 		$554K Buy
12,416
+4,869
+65% +$231K 0.1% 98
2021
Q3 		$381K Buy
7,547
+4,139
+121% +$233K 0.08% 114
2021
Q2 		$267K Buy
+3,408
New +$211K 0.05% 130

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Arthur M. Cohen & Associates's DNLI Position: Q1 2024 in Review

Arthur M. Cohen & Associates sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 10,564 shares — an estimated $227K sold.

Arthur M. Cohen & Associates first reported a position in DNLI in Q2 2021 and held it in 11 quarters. The position peaked at $624K in Q2 2023. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Arthur M. Cohen & Associates reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Arthur M. Cohen & Associates sold 10,564 Denali Therapeutics shares in Q1 2024, an estimated $227K.
  • Arthur M. Cohen & Associates first reported a position in Denali Therapeutics in Q2 2021 and held it in 11 quarters.
  • Arthur M. Cohen & Associates's Denali Therapeutics position peaked at $624K in Q2 2023.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Arthur M. Cohen & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.